Author/Authors :
Malmasi, Abdolali Department of Internal Medicine - Faculty of Veterinary Medicine - University of Tehran, Tehran , Ziaie Ardestani, Bijan Department of Internal Medicine - Faculty of Veterinary Medicine - University of Tehran, Tehran , Mohebali, Mehdi Department of Parasitology, Faculty of Public Health - Tehran University of Medical Sciences, Tehran - Center for Research of Endemic Parasites of Iran (CREPI) - Tehran University of Medical Sciences , Akhoundi, Behnaz Department of Parasitology, Faculty of Public Health - Tehran University of Medical Sciences, Tehran - Center for Research of Endemic Parasites of Iran (CREPI) - Tehran University of Medical Sciences , Ziaie, Shadi Department of Clinical Pharmacy - Faculty of Pharmacy - Shahid Beheshti University of Medical Sciences, Tehran , Masoudifard, Majid Department of Radiology - Faculty of Veterinary Medicine - University of Tehran , Khorram Khorshid, Hamidreza Genetic Research Center - University of Social Welfare and Rehabilitation Sciences, Tehran , Nasiri, Mehdi Department of Clinical Pathology - Faculty of Veterinary Medicine - University of Tehran, Tehran , Bayanolhagh, Saeed Iranian Research Center for HIV/AIDs (IRCHA) - Tehran University of Medical Sciences, Tehran , Mostafavi, Ehsan Department of Epidemiology - Pasteur Institute of Iran, Tehran , Delrobai, Moin Department of Internal Medicine - Faculty of Veterinary Medicine - University of Tehran, Tehran , Siavashi, Vahid Department of Biochemistry - Faculty of Basic Siences - University of Gilan, Rasht
Abstract :
Toxicity and drug resistance against pentavalent antimonials, medications of choice in
treatment of leishmaniasis for more than 5 decades, have become important subjects globally. This study was a randomized, open labeled trial that was designed to determine efficacy and safety of IMOD as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis (CVL). Twenty healthy mongrel dogs were infected with Iranian strain of L. Infantum amastigotes and randomly divided to 5 groups with four animals for each included on: I: negative control (non-infected) II: Glucantime® III: Glucantime® plus IMOD (immune-chemotherapy) IV: IMOD and V: positive control (non-treated). Physical examination, hematological, biochemical,
serological, parasitological, pathological and imaging evaluations were performed pre-/postinterventions every month for 3 months. Comparing with control groups (I&V), immune-chemotherapy group (Glucantime® plus IMOD) showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors. Based on our results, using IMOD in combination with meglumine antimoniate (Glucantime®) has significantly improved CVL than the latter drug alone. So, it
seems this new herbal medicine is useful as adjuvant therapy for canine visceral leishmaniasis.
Keywords :
Dog , Visceral leishmaniasis , IMOD , Meglumine antimoniate , Treatment
